Vidarbha News

Anthrax Pipeline Landscape Analysis: 10+ Key Players & 10+ Pipeline Drugs

 Breaking News
  • No posts were found

Anthrax Pipeline Landscape Analysis: 10+ Key Players & 10+ Pipeline Drugs

November 16
22:45 2022
Anthrax Pipeline Landscape Analysis: 10+ Key Players & 10+ Pipeline Drugs

DelveInsight’s, “Anthrax Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Anthrax Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Anthrax Pipeline Insight Report

  • DelveInsight’s Anthrax Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ Anthrax Pipeline treatment therapies.
  • The leading Anthrax Companies are working such as GC Pharma, Emergent BioSolutions, BlueWillow Biologics, Paratek Pharmaceuticals, Altimmune, Greffex, Planet Biotechnology, Integrated BioTherapeutics, DEINOVE, Hawaii Biotech, VLP Biotech, Aphios Corporation, Enesi, and others.
  • Promising Anthrax Pipeline therapies such as BW-1010: 50 µg – sprayer – IN, AV7909, BioThrax, Ad4-PA-1, PA83-FhCMB, NP-015, rPA vaccine containing alhydrogel, and others
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.

 

Request a sample and discover the recent advances in Anthrax Medication @ Anthrax Treatment Landscape

 

Anthrax Overview

Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Anthrax can be found naturally in soil and commonly affects domestic and wild animals around the world. Although it is rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Anthrax can cause severe illness in both humans and animals.

 

Recent Developmental Activities in the Anthrax Pipeline Report

  • The vaccine candidate AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. AV7909 is comprised of Anthrax Vaccine Adsorbed (AVA) in combination with an adjuvant. The vaccine is currently in phase III stage of development.
  • GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder. This vaccine is obtained by cultivating and purifying genetically engineered Bacillus brevis. In the phases 1 and 2 of clinical trials, GC1109 has displayed an excellent safety profile and dose-dependent immunogenicity. Currently, it is in phase II stage of development.

 

Anthrax Emerging Drugs

  • GC1109: GC Pharma
  • AV7909: Emergent BioSolutions

 

Learn more about the emerging Anthrax pipeline therapies @ Anthrax Clinical Trials

 

Anthrax Pipeline Therapeutic Analysis

There are approx. 10+ key companies which are developing the therapies for Anthrax. The companies which have their Anthrax drug candidates in the most advanced stage, i.e. phase III include, Emergent BioSolutions.

 

Scope of the Anthrax Pipeline Report

  • Coverage- Global
  • Anthrax Pipeline Assessment by Product Type
  • Anthrax Pipeline Assessment by Stage and Product Type
  • Anthrax Pipeline Assessment by Route of Administration
  • Anthrax Pipeline Assessment by Stage and Route of Administration
  • Anthrax Pipeline Assessment by Molecule Type
  • Anthrax Pipeline Assessment by Stage and Molecule Type
  • Anthrax Pipeline Companies- GC Pharma, Emergent BioSolutions, BlueWillow Biologics, Paratek Pharmaceuticals, Altimmune, Greffex, Planet Biotechnology, Integrated BioTherapeutics, DEINOVE, Hawaii Biotech, VLP Biotech, Aphios Corporation, Enesi, and others.
  • Anthrax Pipeline Therapies- BW-1010: 50 µg – sprayer – IN, AV7909, BioThrax, Ad4-PA-1, PA83-FhCMB, NP-015, rPA vaccine containing alhydrogel, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anthrax: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anthrax – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anthrax Collaboration Deals
  9. Late Stage Products (Phase III)
  10. AV 7909: Emergent BioSolutions
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. GC1109: GC Pharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Intransal anthrax vaccine: Altimmune
  17. Inactive Products
  18. Anthrax Key Companies
  19. Anthrax Key Products
  20. Anthrax- Unmet Needs
  21. Anthrax- Market Drivers and Barriers
  22. Anthrax- Future Perspectives and Conclusion
  23. Anthrax Analyst Views
  24. Anthrax Key Companies
  25. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Anthrax drugs?
  • How many Anthrax drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anthrax?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anthrax therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anthrax and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Dive deep into rich insights into new Anthrax Emerging Therapies, visit @ Anthrax Pipeline Drugs

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/